Urine test to predict kidney cancer response to immunotherapy
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study uses an at-home-style urine test (urine “omics,” meaning detailed lab information) to help predict how well immunotherapy may work for advanced kidney cancer. If you join, your urine results may help doctors tailor treatment choices and better understand who benefits most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re older than 20 years
- You have advanced or metastatic kidney cancer (renal cell carcinoma)
- You are about to start immunotherapy (IO-based therapy)
- You can do daily activities at a study-approved level (ECOG 0–3)
- Your kidney function is not too low (eGFR above 15)
- You can sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
This study uses urine “omics” tests (detailed lab patterns from urine) to predict whether immunotherapy will work for people with metastatic urothelial (bladder/urinary tract) cancer. It may help doctors choose the right treatment sooner by identifying who is more likely to benefit.
This study tests whether a simple blood test that tracks tumor DNA (called ctDNA) can help predict how well immunotherapy will work for people with non-clear cell kidney cancer. If you are about to start immunotherapy for advanced disease, this study could help your doctor better understand your treatment response.
This trial studies whether removing the primary kidney tumor (cytoreductive nephrectomy) in addition to standard immunotherapy treatment can help people with metastatic kidney cancer. It is for patients whose cancer has not gotten worse after 6 months of initial treatment.
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
Hear when a new Metastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.